Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.